Search

Home > FierceBiotech Radio > GlaxoSmithKline's horrible, no good, very bad year; Kyle Bass' 'truthful irrelevancy'; and the return of vanity pharma websites
Podcast: FierceBiotech Radio
Episode:

GlaxoSmithKline's horrible, no good, very bad year; Kyle Bass' 'truthful irrelevancy'; and the return of vanity pharma websites
Category: Science & Medicine
Duration: 00:26:36
Publish Date: 2015-09-10 23:00:00
Description:

Fierce editors discuss the latest setback in a bad run of form for GlaxoSmithKline, Kyle Bass' trouble with drug patents, and a new twist in the buyout battle between Horizon Pharma and Depomed.
Total Play: 0